Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
AZD0120’s first pivotal trial will test settings as early as the second line.
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
This weekend’s oncology conference will feature at least 30 different ADC projects.
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.
An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.